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License 4.0 (CC BY-NC).Mammalian EAK-7 activates alternative mTOR signaling
to regulate cell proliferation and migration
Joe Truong Nguyen,1,2 Connor Ray,1,2 Alexandra Lucienne Fox,1,2 Daniela Baccelli Mendonça,1,2
Jin Koo Kim,1,2,3 Paul H. Krebsbach1,2,3*
Nematode EAK-7 (enhancer-of-akt-1-7) regulates dauer formation and controls life span; however, the function
of the human ortholog mammalian EAK-7 (mEAK-7) is unknown. We report that mEAK-7 activates an alternative
mechanistic/mammalian target of rapamycin (mTOR) signaling pathway in human cells, in which mEAK-7 inter-
acts with mTOR at the lysosome to facilitate S6K2 activation and 4E-BP1 repression. Despite interacting with
mTOR and mammalian lethal with SEC13 protein 8 (mLST8), mEAK-7 does not interact with other mTOR complex
1 (mTORC1) or mTOR complex 2 (mTORC2) components; however, it is essential for mTOR signaling at the lysosome.
This phenomenon is distinguished by S6 and 4E-BP1 activity in response to nutrient stimulation. Conventional S6K1
phosphorylation is uncoupled from S6 phosphorylation in response to mEAK-7 knockdown. mEAK-7 recruits mTOR
to the lysosome, a crucial compartment for mTOR activation. Loss of mEAK-7 results in a marked decrease in lyso-
somal localization of mTOR, whereas overexpression of mEAK-7 results in enhanced lysosomal localization of mTOR.
Deletion of the carboxyl terminus of mEAK-7 significantly decreases mTOR interaction. mEAK-7 knockdown de-
creases cell proliferation and migration, whereas overexpression of mEAK-7 enhances these cellular effects.
Constitutively activated S6K rescues mTOR signaling in mEAK-7–knocked down cells. Thus, mEAK-7 activates an
alternative mTOR signaling pathway through S6K2 and 4E-BP1 to regulate cell proliferation and migration.INTRODUCTION
Evolution demonstrates that fundamental signaling pathways in eu-
karyotes are conserved through orthologous and paralogous genes. In
Caenorhabditis elegans, EAK-7 (enhancer-of-akt-1-7) negatively regu-
lates DAF-16/FoxO and functions in parallel with insulin receptor
signaling/Akt to affect nematode dauer formation and life span (1).
However, how EAK-7 imparts these effects inmammals is unknown.
In humans, insulin receptor signaling also controls diverse signaling
cascades related to cell growth, proliferation, and survival (2). One of
these vital metabolic signaling cascades is the mechanistic/mammalian
target of the rapamycin (mTOR) signaling pathway. On an expedition-
ary search for novel antibiotic compounds in the South Pacific, rapamy-
cin was discovered on Rapa Nui and was found to block yeast growth
and to have strong immunosuppressive effects in mammals (3). Rapa-
mycin was subsequently shown to form a complex with FKBP12,
which resulted in a gain of function that inhibited signal transduction
pathways required for cell growth and proliferation (4). TOR/mTOR
was identified as the target of the rapamycin-FKBP12 inhibitory
complex responsible for repressing protein production and cell me-
tabolism in yeast (5) and eukaryotes (6). Since then, laboratories across
the world have demonstrated the essential role of mTOR signaling in
eukaryotic development and disease in response to nutrient sensing (3).
TOR/mTORwas identified as amember of the phosphatidylinositol-3
kinase–related kinase family (7). mTOR signaling diverges into two known
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) in mammals (3) as well as TOR1 and TOR2 in yeast (8).
Both complexes act at the lysosome, an essential cellular compartment
for mTOR signaling, but govern different cellular processes. Upstream
of mTORC1, the tuberous sclerosis complex integrates biologic inputs
such as low energy levels and growth factor activation (9). However, formTORC1 to be fully activated, it must be recruited to the lysosome
through amino acid signaling via the Rag guanosine triphosphatase
(GTPase) Rag A or B, which dimerizes with either Rag C or D (10). In
the amino acid–starved state, mTOR is diffuse within the cell, but amino
acid stimulation is sufficient to allow the Ragulator-Rag complex to re-
cruitmTOR to the lysosome (11). Thus, the culmination of these nutrient
signals allows for Rheb GTPase to activate mTOR at the lysosome (12).
We focused on mTORC1 signaling because it integrates metabolic
processes to affect macromolecular biosynthesis, growth, and protein
synthesis (3). Dysregulation of the aforementioned mechanisms pro-
motes cancer formation and progression, and aberrant mTORC1 sig-
naling is implicated in thepathogenesis of humandisease (3). Independent
reports reveal that human EAK-7 mRNA is overexpressed in diseases
such as hepatocellular carcinoma (13) and lymph node–positive breast
cancers (14). Although these findings are intriguing, their relevance re-
mains unknown and requires further study. BecausemTOR is an essential
effector formanyof these important cellular contexts and functionswithin
the insulin receptor signaling pathway, we hypothesized that the human
ortholog of EAK-7, termed mammalian EAK-7 (mEAK-7), could po-
tentially affect mTOR signaling in human cells.RESULTS
mEAK-7 is an evolutionarily conserved protein
Bioinformatics databases were analyzed to gain insight into the molec-
ular functions ofmEAK-7, also known through genomic and proteomic
studies as KIAA1609 (15), LOC57707 (16), or TLDC1 (TBC/LysM-
associateddomain-containing1) (17).Algorithmic analysis demonstrated
that the amino acid identity of mEAK-7 and EAK-7 is 89% similar
across eukaryotes (Fig. 1A and fig. S1A) (18), suggesting that mEAK-7
is conserved across eukaryotes.
mEAK-7 contains two known domains: the TLD (TBC-containing
and LysM-associated domain) and the N-myristoylation motif (Fig.
1B). TLD domain–containing proteins confer neuroprotection against
oxidative stress through unknown mechanisms (19). Computational1 of 15
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Fig. 1. mEAK-7 is a lysosomal protein, conserved across eukaryotes, and is required formTOR signaling in human cells. (A) Comparison of eukaryoticmEAK-7 orthologs.
(B) Diagramdepicting themEAK-7N-myristoylationmotif and the TLD (TBC/LysM-associated) domain. (C) Immunoblot screen of human cell lines to detectmEAK-7 protein.
(D) Confocal microscopy analysis of H1299 cells stably expressing HA–mEAK-7WT for HA and LAMP2 or LAMP1. Scale bars, 10 mm. (E) Analysis of endogenous colocalization
of mEAK-7 and lysosomal markers in H1299 cells. Scale bars, 25 mm. (F) H1975 cells were treated with control (Ctl) or three unique mEAK-7 siRNAs to assess S6 phospho-
rylation. (G) H1975, MDA-MB-231, and H1299 cells were treated with control (Ctl) or two unique mEAK-7 siRNAs to assess S6 phosphorylation. (H) Cells were treated with
control (Ctl) or mEAK-7 #1 siRNA to assess 4E-BP1 phosphorylation. (I) Cells were treated with control or two unique mEAK-7 siRNAs. Next, cells were starved in DMEM−AAs
for 2 hours, and amino acids, insulin, or both were reintroduced for 30min. (J) Cells were treated with control, mEAK-7 #1, S6K1, and S6K2 siRNA. Next, cells were starved in
DMEM+AAs for 2 hours, and insulin (1 and 10 mM) were reintroduced for 30 min. All experiments were repeated at least three times. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used for loading controls. hESC, human embryonic stem cells.Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018 2 of 15
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sheets (20). The crystal structure of the TLDc domain of oxidation
resistance protein 2 from zebrafish reveals that two antiparallel b sheets
form a central b-sandwich surrounded by two helices and two one-turn
helices (21). The N-myristoylation motif irreversibly attaches myristate
to anchor proteins to lipid bilayers or endomembrane compartments.
Despite this information, the functional relevance of these domains is
not known for mEAK-7.
To investigate the molecular function of mEAK-7, we verified an
antibody that detects endogenous mEAK-7 in human cells (fig. S1B),
and we identified cells that express endogenous mEAK-7 protein
(Fig. 1C and fig. S1C). mEAK-7 protein was detected in UM-SCC-1,
H1975, MDA-MB-231, H1299, HCC1937, MDA-MB-436, SUM149,
MDA-MB-468, UM-SCC-10A, UM-SCC-11A, UM-SCC-17B, and
UM-SCC-81B (Fig. 1C and fig. S1C). Through this limited human cell
screen, we detected mEAK-7 in many human cell lines.
mEAK-7 is anchored at the lysosomal membrane
mEAK-7 has been identified in membrane-bound/organelle fractions
(22) and lysosomal fractions (16), but definitive evidence of the precise
cellular compartment where mEAK-7 resides has not yet been demon-
strated. By generatingH1299 cell lines with stably expressed C-terminal
hemagglutinin (HA)–tagged mEAK-7 (HA–mEAK-7WT) and costaining
with antibodies that recognize compartment-specific proteins, we
determined that HA–mEAK-7WT strongly colocalizes with lysosomal-
associatedmembraneprotein–2 (LAMP2, lysosome), LAMP1 (lysosome),
and, to a lesser extent, the plasmamembrane (Fig. 1D). Green fluorescent
protein–tagged EAK-7 in nematodes exhibited fluorescence in the plasma
membrane of the pharynx, nervous system, intestine, body wall muscle,
hypodermis, vulva, and a group of cells near the anus (1). However,
subcellular localization at the lysosome has not been demonstrated
in nematodes.
We observed little to no colocalization of HA–mEAK-7WT in the
endosome (fig. S2A), mitochondria (fig. S2B), endoplasmic reticulum
(fig. S2C), and Golgi complex (fig. S2D). However, overexpression of
exogenous protein can sometimes result in nonspecific targeting to ran-
dom cell compartments. Thus, we validated an antibody that targets
endogenous mEAK-7 to determine the physiological localization
within cells (fig. S3, A and B). We demonstrated that endogenous
mEAK-7 strongly colocalizes with endogenous LAMP1 and LAMP2
(Fig. 1E). These data illustrate that mEAK-7 is principally a lysosomal
protein, an essential cellular compartment for mTORC1 signaling (23).
mEAK-7 supports mTORC1 signaling in response
to nutrients
mTORC1 localizes to the lysosome in response to nutrient stimulation,
and this process is required for mTOR function (12). Further insights
guiding our hypothesis that mEAK-7 may be an effector of mTORC1
signaling include the observations that nematode EAK-7 functions
within the insulin receptor signaling pathway (1), mEAK-7 is primarily
a lysosomal protein (Fig. 1, D and E), andmTORC1 is the core complex
for this signaling pathway at the lysosome (23).
To test the extent to which mEAK-7 functions in mTORC1 sig-
naling, we treated H1975 cells with three unique mEAK-7 small inter-
fering RNAs (siRNAs) for 48 hours in 10% serum-containingDulbecco’s
minimum essential medium (DMEM+serum). mEAK-7 knockdown
substantially decreased (Ser240/244) phospho (p)–S6 levels, an indicator
of activated mTORC1 signaling (24), revealing mEAK-7 functions in
mTORC1 signaling under DMEM+serum conditions (Fig. 1F). To deter-Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018mine whether this was a universal phenomenon, we treated H1975,
MDA-MB-231, and H1299 cells with two unique mEAK-7 siRNAs,
which resulted in acutely diminished (Ser240/244) p-S6 levels (Fig. 1G).
Finally,H1299 cells were treatedwithmEAK-7 siRNA, starved of serum
for 2 hours in DMEM-containing amino acids (DMEM+AAs), and re-
introduced to serum for 24 hours.mEAK-7–knocked downH1299 cells
failed to activate and sustain (Ser240/244) p-S6 levels in response to serum
stimulation (fig. S4A). Together, these data indicate thatmEAK-7 is im-
portant for basal-level and serum-mediated mTORC1 signaling in
mEAK-7+ cells.
mTORC1 regulates cap-dependent protein translation by phos-
phorylating the eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1) at Thr37/46, which primes the 4E-BP1 phospho-
rylation site at Ser65 and Thr70, and allows 4E-BP1 detachment from
eukaryotic translation initiation factor 4E (eIF4E) (25). Because
mEAK-7 supports S6 phosphorylation through mTOR, we sought
to assess the functional status of 4E-BP1, a major target of mTOR.
To test the effects of mEAK-7 on 4E-BP1 phosphorylation, we treated
H1975, MDA-MB-231, H1299, and human embryonic kidney (HEK)–
293T cells with control ormEAK-7 siRNA for 48 hours in DMEM+serum.
mEAK-7 knockdown appreciably decreased (Ser65) p–4E-BP1, (Thr37/46)
p–4E-BP1, and (Thr70) p–4E-BP1 levels (Fig. 1H). mEAK-7–knocked
down H1299 cells also failed to activate and sustain (Ser65) p–4E-BP1
levels in response to serum stimulation (fig. S4A). Thus, data suggest that
mEAK-7 is capable of regulating both S6 and 4E-BP1, two primary
markers for mTORC1 signaling.
mTORC1 signaling is stimulated amino acids and/or insulin at the
lysosome (12). To address the possibility that mEAK-7 regulates
mTORC1 signaling in response to specific nutrients, we starved cells
for 2 hours in custom-manufactured DMEM lacking amino acids
(DMEM−AAs). Subsequently, cells were collected as a starved control
or collected after reintroduction of amino acids, insulin, or both. Con-
trol siRNA–treated H1975, MDA-MB-231, H1299, and HEK-293T cells
increasedmEAK-7protein levels that correlatedwith increased (Ser240/244)
p-S6 levels in response to all nutrient conditions (Fig. 1I and fig. S5).
mEAK-7 protein levels also increased after serum reintroduction at dif-
ferent time points following serum starvation in H1299 cells (fig. S4A).
Thus, serum, amino acids, and insulin increase mEAK-7 protein levels.
H1975, MDA-MB-231, H1299, and HEK-293T cells treated with
mEAK-7 siRNA demonstrated reduced (Ser240/244) p-S6 levels under
all conditions (Fig. 1I and fig. S5). In addition,mEAK-7–knocked down
H1299 cells displayed an impaired ability to activate and sustain (Ser65)
p–4E-BP1 levels in response to amino acid and insulin stimulation over
time (fig. S4B). Together, these data suggest that mEAK-7 can regulate
mTORC1 signaling in response to serum, amino acids, and insulin and
that mEAK-7 protein is influenced by nutrient stimulation. Although
HEK-293T cells, a widely used cell line to study mTOR signaling,
exhibits comparatively low mEAK-7 protein levels (fig. S4C), mEAK-7
knockdown still led to a significant reduction in mTOR signaling, as
demonstrated by S6 and 4E-BP1 phosphorylation.
mEAK-7 functions through S6K2 rather than S6K1
Upon further examination of mEAK-7 function in mTORC1 sig-
naling, we obtained evidence that was unexpectedly contrary to our
initial hypothesis. After knocking down mEAK-7, we discovered
that whereas (Ser240/244) p-S6 levels were decreased, (Thr389) p-S6K1
levels were increased (Fig. 1I and figs. S4, A and D, and S5). Because
(Thr389) p-S6K1 is used as a reliable indicator of mTORC1 signaling,
these findings appear to uncouple S6K1 activity from (Ser240/244) p-S63 of 15
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(Thr389) p-S6K1 regulation in response to amino acid and/or insulin
stimulation, whereas H1975, MDA-MB-231, and H1299 cells exhibited
aberrantly functioning S6K1 (Fig. 1I and fig. S5). Thus, an alternative
kinase may exist to compensate for dysregulated S6K1 activity in
H1975, MDA-MB-231, and H1299 cells.
To investigate this perceived molecular anomaly, we examined
S6K2, an understudied target of mTORC1. S6K1 is a prominent target
of mTOR, but mTOR also targets S6K2, a closely related homolog of
S6K1 (26). It is believed that the role of S6K2 is redundant to S6K1,
but emerging evidence suggests that these kinases also have distinct
functions. S6K1−/− cells are capable of regulating (Ser240/244) p-S6 levels,
whereas S6K2−/− cells fail to regulate (Ser240/244) p-S6 levels, demon-
strating that S6K1 may not always be the primary kinase linked to
(Ser240/244) p-S6 levels (27). Furthermore, S6K2 knockout mice and
S6K2 siRNA–treated cells exhibit increased S6K1 function, demonstrated
by a stark increase in (Thr389) p-S6K1 levels (28). These data suggest that
S6K2may play a vital role inmTOR signaling. Therefore, we investigated
the extent to which S6K1 and S6K2 may be linked to (Ser240/244) p-S6
levels in mEAK-7+ cells.
To elucidate the roles of S6K1 and S6K2, we analyzed (Ser240/244)
p-S6 levels in response to insulin stimulation after knockdown of
mEAK-7, S6K1, or S6K2. Cells were starved for 2 hours in DMEM+AAs
without serum and subsequently introduced to insulin at 1 or 10 mM
for 30min. InH1975 andMDA-MB-231 cells,mEAK-7 or S6K2 knock-
down markedly reduced (Ser240/244) p-S6 levels, but S6K1 knockdown
had a lesser effect (Fig. 1J and fig. S6, A and B). We observed that
mEAK-7 or S6K2 knockdown markedly increased (Thr389) p-S6K1
levels, which suggests the uncoupling of S6K1 on (Ser240/244) p-S6 levels
in some cell contexts (Fig. 1J and fig. S6, A and B).
In contrast, S6K1 affects (Ser240/244) p-S6 levels to a greater degree in
H1299 and HEK-293T cells, although mEAK-7 or S6K2 knockdown
substantially abrogated (Ser240/244) p-S6 levels (Fig. 1J and fig. S6, C
and D). These findings suggest that most mEAK-7+ cell lines function
primarily through S6K2, rather than S6K1, to activate mTOR signaling.
In addition, differential levels of mEAK-7 protein (fig. S4C) were not
predictive of whether cell lines will favor S6K2 over S6K1 in mTORC1-
mediated signaling. These findings are consistent with reports that S6K1
and S6 phosphorylation are not exclusively linked and that S6K2 has
additional biological roles in eukaryotes (28).
Molecular analysis of mEAK-7 demonstrates the role of
the TLD domain and C terminus as crucial regulators
of mEAK-7 function
To rule out the possibility that siRNA-mediated knockdown ofmEAK-7
nonspecifically influences mTORC1 signaling, we transduced H1975,
MDA-MB-231, H1299, and HEK-293T cells with pLenti-III-HA-
control or pLenti-III-HA(C-terminus)–mEAK-7WT lentivirus and selected
these cells with puromycin (1 mg/ml) for 2weeks.Wedemonstrated that
overexpression of HA–mEAK-7 activatedmTORC1 signaling in H1975,
MDA-MB-231, H1299, and HEK-293T cells (Fig. 2A). Thus, both
knockdown and overexpression studies demonstrated that mEAK-7 is
an essential component of mTORC1 signaling in mEAK-7+ cells.
Next, we investigated themolecular domains necessary formEAK-7
function. To assess themEAK-7 domains essential formTOR signaling,
we generated several mutants and transduced them with lentivirus
into cells that expressed endogenous mEAK-7 (Fig. 2B). We compared
HA–mEAK-7WT with HA–mEAK-7 mutants for LAMP2 colocaliza-
tion at the lysosome (Fig. 2, C to H).We also investigated differentialNguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018overexpression effects of wild type (WT) andmutants onmTOR sig-
naling stimulated by amino acids and/or insulin (Fig. 2, I and J). HA–
mEAK-7WT colocalized with LAMP2 (Fig. 2C), amino acids, and insulin
stimulation successfully induced (Ser240/244) p-S6 in WT overexpres-
sing H1299 cells (Fig. 2I).
HA–mEAK-7G2A, a mutant with a point mutation that replaces
the first glycine residue with alanine within theN-myristoylation motif,
failed to anchor to the lysosome (Fig. 2D). However, amino acids and
insulin stimulation induced (Ser240/244) p-S6, possibly because of en-
dogenous mEAK-7 function (Fig. 2I). Deletion of amino acids 1 to 139
(HA–mEAK-7DNDEL1) also led to a lysosomal anchorage defect (Fig.
2E), due to the loss of theN-myristoylationmotif, but did not significantly
alter endogenousmTORC1 signaling (Fig. 2I).HA–mEAK-7DNDEL2 co-
localized with LAMP2 (Fig. 2F) and also did not significantly alter
endogenous mTORC1 signaling (Fig. 2I).
Although both HA–mEAK-7DTLD and HA–mEAK-7DCDEL localize
at the lysosome (Fig. 2, G andH), stable expression of either HA–mEAK-
7DTLD or HA–mEAK-7DCDEL inhibited the induction of (Ser240/244) p-S6
levels by amino acids and insulin (Fig. 2, I and J), and resulted in increased
(Thr389) p-S6K1 levels (Fig. 2J). Although it is unclear how these mutants
affect endogenous mEAK-7 function to impair mTOR signaling, these
results demonstrate that the TLD domain and C terminus are necessary
for mEAK-7–mediated mTOR function.
mEAK-7 recruits mTOR to the lysosome under
nutrient-deprived and nutrient-rich conditions
mTOR signaling components are translocated to the lysosome in re-
sponse to nutrient stimulation, and this shuttling is necessary to activate
mTORC1 signaling (3). Because mEAK-7 is predominantly lysosomal,
we posited a role for mEAK-7 in targeting mTOR to the lysosome. To
determine the role of mEAK-7 in lysosomal localization of mTOR,
H1299 cells were treated with control or mEAK-7 siRNA for 48 hours.
Subsequently, cells were starved in DMEM−AAs for 1 hour, and amino
acids and insulinwere reintroduced for 30min.We found thatmEAK-7
knockdown impaired mTOR localization to the lysosome (Fig. 3A),
confirming that mEAK-7 is important for mTOR localization. Al-
though low levels of mTOR remained capable of migrating to the
lysosome after mEAK-7 knockdown, this might have been due to
residual mEAK-7 still expressed because siRNA treatment is not 100%
effective and because other major regulators of mTOR, such as the Rag
GTPases, have been shown to recruit mTOR to the lysosome (11).
Further analysis demonstrated that the expression of mTORC1/2
components was not altered after mEAK-7 siRNA treatment (Fig.
3B). H1299 cells treated with mEAK-7 siRNA demonstrated a statis-
tically significant decrease in mTOR/LAMP2 colocalization under the
starved condition (Fig. 3C). Under the nutrient-replenished condition,
H1299 cells treated with mEAK-7 siRNA also exhibited a statistically
significant decrease inmTOR/LAMP2 colocalization (Fig. 3C). To sub-
stantiate this finding, we performed the reciprocal experiment by over-
expressingHA–mEAK-7. HA–mEAK-7 overexpression inH1299 cells
resulted in a statistically significant increase in mTOR/LAMP2 colo-
calization in the absence of nutrients (Fig. 3, D and E). In addition,
reintroduction of nutrients in control cells resulted in a significant en-
hancement of the colocalization of mTOR/LAMP2, and HA–mEAK-7
overexpression increasedmTOR/LAMP2 colocalization in the presence
of nutrients (Fig. 3, D and E). Further analysis demonstrated that
nutrient reintroduction did not result in a statistically significant change
of HA–mEAK-7/LAMP2 colocalization (Fig. 3F). We then hypothe-
sized that endogenous mEAK-7 would colocalize with endogenous4 of 15
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SC I ENCE ADVANCES | R E S EARCH ART I C L EmTOR in response to nutrient stimulation because amino acids recruit
mTOR to the lysosome.H1299 cells were nutrient-starved for 1 hour and
stimulated with amino acids, insulin, or both for 1 hour. Endogenous
mEAK-7 and endogenous mTOR strongly colocalized in response to
nutrient stimulation (fig. S7, A to E).
We hypothesized that mEAK-7 could directly affect mTOR kinase
function, possibly as an adaptor protein. mTOR interaction with its
complex components is known to be sensitive under different buffer
conditions (29). To rule out the possibility of nonspecific or artificial
interactions due to an abundance of exogenously produced protein
and buffer-dependent conditions, we harvested either H1299 or HA–
mEAK-7–expressing H1299 cells, in either NP-40 or CHAPS buffer.
Thus, we assessed the potential for interaction between these two pro-
teins using a coimmunoprecipitation assay. Coimmunoprecipitation of
exogenous HA–mEAK-7WT confirmed significant interaction with en-
dogenous mTOR, compared to an immunoglobulin G (IgG) control
under serum-containing conditions (Fig. 4A). In addition, endoge-
nous mEAK-7 interacted with endogenous mTOR (Fig. 4B). Finally,
knockdown of mEAK-7 diminished the interaction of endogenous
mEAK-7 with endogenous mTOR and mammalian lethal with SEC13
protein 8 (mLST8) (Fig. 4C and fig. S8A). However, mEAK-7 failed
to interact with regulatory associated protein of mTOR (raptor) or
rapamycin-insensitive companion ofmTOR (rictor), key components of
mTORC1 and mTORC2, respectively. Intriguingly, exogenous HA–
mEAK-7WT also interactedwithmTORandmLST8but did not interact
with rictor, Sin1, raptor, proline-rich AKT1 substrate 1 (PRAS40), or
DEPTOR (Fig. 4D). These findings suggest the possibility of an alter-
native mTOR complex that is yet to be identified in mammalian cells.
To assess the nutrient dependency of this interaction, we starved
HA–mEAK-7WT cells for 2 hours and reintroduced amino acids, insulin,
or both for 30min. All lysates for immunoprecipitation were collected in
NP-40 lysis buffer, unless noted otherwise. Under these conditions, ex-
ogenousHA–mEAK-7WT and endogenousmTOR interacted under the
starved condition, and this interaction was increased by nutrient stim-
ulation (Fig. 4E and fig. S8B). To further demonstrate the validity of
these nutrient-dependent interactions, data support that endogenous
mEAK-7 also strongly interacts with endogenous mTOR under the
amino acid and insulin or amino acid and serum conditions (Fig. 4F
and fig. S8C). In addition, coimmunoprecipitation of endogenous
mTOR to detect exogenous HA–mEAK-7WT also confirmed that this
interaction increased under nutrient stimulation (Fig. 4G and fig. S8D).
Therefore, data suggest that both exogenous and endogenous mEAK-7
are capable of interacting with mTOR.
To determine themolecular domain necessary for mEAK-7 interac-
tion with mTOR, we performed coimmunoprecipitation in cells stably
expressing HA–mEAK-7WT, HA–mEAK-7DTLD, and HA–mEAK-
7DCDEL, because these domains are necessary for the activation of
mTORC1 signaling in mEAK-7+ cells (Fig. 2, I and J). We found that
the C-terminal protein region is necessary for the interaction of ex-
ogenousHA–mEAK-7WTandendogenousmTOR(Fig. 4Hand fig. S8E),
so this region of the C terminus was termed the mTOR-binding (MTB)
domain. Other mEAK-7 mutants were also capable of interacting with
endogenous mTOR, suggesting that maintaining an intact MTB domain
is sufficient formTORbinding (fig. S7, F andG). In addition, overexpres-
sion of HA–mEAK-7DTLD and HA–mEAK-7DCDEL increased (Thr389)
p-S6K1 levels (Fig. 4H). These findings suggest that the interaction of
mEAK-7 and mTOR diverts mTOR targeting from S6K1 to S6K2,
whereas loss of mEAK-7 diverts mTOR targeting from S6K2 to S6K1,
resulting in increased (Thr389) p-S6K1 levels.Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018We hypothesized that mEAK-7 regulates mTORC1 signaling
through S6K2 because (Thr389) p-S6K1 levels were not linked to its
downstream target, (Ser240/244) p-S6 (Figs. 1, I and J, and 2J, and fig. S4,
A and D). To assess this possibility, we transiently transfected H1299
cells with pcDNA3-HA-S6K2-WT and either control or mEAK-7 siRNA
and immunoprecipitated HA-S6K2. mEAK-7 knockdown considerably
decreased the interaction between endogenous mTOR and HA-S6K2
(Fig. 4I and fig. S8F). To ensure mEAK-7 specificity in this interaction,
we used two mEAK-7 siRNAs, and both demonstrated a substantial
decrease in HA-S6K2 interaction with mTOR (Fig. 4J and fig. S8G).
These outcomes suggest that mEAK-7 supports the interaction of S6K2
and mTOR.
Next, we hypothesized that mEAK-7 may also influence S6K1 and
mTOR interaction. To test this, we transiently transfected H1299 cells
withpRK7-HA-S6K1-WTand control ormEAK-7 siRNAand immuno-
precipitated HA-S6K1. mEAK-7 knockdown increased the interaction
of exogenousHA-S6K1with endogenousmTOR (Fig. 4K and fig. S8H).
Subsequently, two different mEAK-7 siRNAs confirmed that these
enhanced interactions were the result of mEAK-7 knockdown (Fig. 4L
and fig. S8I). Thus, we demonstrate that mEAK-7 intricately controls
mTOR interaction with both S6K2 and S6K1.
Although these data support the necessity of mEAK-7 for the inter-
action ofmTORwith S6K2, they do not provide direct evidence of S6K2
function. To our knowledge, an antibody specific to (Thr388) p-S6K2
does not exist. However, the amino acid sequences of the hydrophobic
motifs of the S6Ks (Fig. 4M) are nearly identical. Given this similarity,
we predicted that the monoclonal antibody against (Thr389) p-S6K1
[Cell Signaling Technology (CST), clone 108D2] would reveal the rela-
tive phosphorylation status of S6K2, because it was designed to target
the mTOR-targeting hydrophobic motif, and this is a strategy used by
other groups (30). Because (Thr389) p-S6K1 levels are a common readout
of S6K1 kinase activity and mTORC1 functionality, we expected that
(Thr388) p-S6K2 levels would also indicate S6K2 kinase activity in this
context. In addition, the mass of S6K1 and S6K2 are different in that
S6K1 is 65 to 70 kDa and S6K2 is 60 kDa; therefore, immuno-
precipitation would yield detectable phosphorylation differences of the
concentrated kinase. To determine the phosphorylation status of S6K2
by mEAK-7, we transiently transfected H1299 cells with pcDNA3-
HA-S6K2-WT and either control or mEAK-7 siRNA, starved of nutri-
ents, and we reintroduced DMEM+serum for 30 min. HA-S6K2 was then
immunoprecipitated and probed with the 108D2 antibody. Data suggest
that mEAK-7 is required for the interaction of mTOR with S6K2 in re-
sponse to serum and regulates (Thr388) p-S6K2 levels, as demonstrated
by a loss of S6K2 phosphorylation in response to mEAK-7 knockdown
(Fig. 4M). Furthermore, loss of mEAK-7 diminished S6K2-mediated
phosphorylationof S6 in response to serumstimulation (Fig. 4M).There-
fore, mEAK-7 is required for S6K2 activity in these cells.
Finally, to demonstrate the extent to which mEAK-7 regulates 4E-
BP1 and eIF4E interaction, we treatedH1299 cells with either control or
mEAK-7 siRNA and immunoprecipitated eIF4E. We discovered that
mEAK-7 knockdown enhanced binding of 4E-BP1 to eIF4E (Fig. 4N
and fig. S8J). Thus, these data establish mEAK-7 as a novel effector of
mTOR signaling that regulates both S6K2 activity and 4E-BP1 activity.
mEAK-7 supports cell proliferation and migration
After demonstrating that mEAK-7 supports mTOR signaling, we hy-
pothesized that mEAK-7 was essential for critical cellular functions
governed bymTOR.mTOR signaling is important for regulation of cell
number (3). To elucidate the influence of mEAK-7 on proliferation,7 of 15
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SC I ENCE ADVANCES | R E S EARCH ART I C L Ecells were treated with either control or mEAK-7 siRNA and counted
after 3 and 5 days. In H1975 (Fig. 5A), MDA-MB-231 (Fig. 5B), H1299
(Fig. 5C), andHEK-293T cells (Fig. 5D), treatment withmEAK-7 siRNA
resulted in a significant reduction in cell proliferation. Further, annexinV
staining or acridine orange–propridium iodide (AO-PI) staining demon-
strated no difference in cell death after mEAK-7 knockdown (fig. S9,
A to C). Previous reports corroborate the finding that the loss of TLD
domain–containing proteins (19) or single knockdownof S6K2without
an apoptotic stimulator (31) does not result in significant levels of cell
death. Because of the low expression of mEAK-7 in some human cells,
we hypothesized thatmEAK-7 overexpressionwould promote cell pro-
liferation. Thus, to test the effect ofmEAK-7 overexpression on cell pro-
liferation,we transducedH1975,MDA-MB-231,H1299, andHEK-293T
cells with pLenti-GIII-CMV-control-HA and pLenti-GIII-CMV–mEAK-
7–HA. Overexpression of HA–mEAK-7 in H1975 (Fig. 5E), MDA-MB-
231 (Fig. 5F), H1299 (Fig. 5G), and HEK-293T (Fig. 5H) significantly
enhanced cell proliferation at days 3 and 5. Thus, we concluded that
mEAK-7 is vital for cell proliferation in mEAK-7+ cells.
mTORC1 signaling has substantial control over cell migration and
metastasis, with the 4E-BP1–eIF4E axis regulatingmTOR-sensitive mi-
gration and invasion genes (32). Given the role ofmEAK-7 inmTOR
signaling, we investigated the impact of mEAK-7 on cell migration.
H1975, MDA-MB-231, H1299, and HEK-293T cells were treated with
either control or mEAK-7 siRNA and seeded into CIM-plates, which
use xCELLigence technology to quantify cell migration in real time,
collecting hundreds of data points through a dimensionless cell-index
parameter. Cells must pass through a pore embedded in a gold-plated
electric grid, creating electrical impedance and registering a signal for
real-time, quantifiable cellmigration.We proceeded to conduct statistical
analyses at select time points of 12, 24, 36, and 48 hours. Treatment of
H1975 (Fig. 5I), MDA-MB-231 (Fig. 5J), H1299 (Fig. 5K), and HEK-
293T (Fig. 5L) cellswithmEAK-7 siRNAresulted in statistically significant
reductions of real-time cell migration at 24, 36, and 48 hours. In addition,
scratch wound assay analysis of H1975 (Fig. 5M), MDA-MB-231 (Fig.
5N), H1299 (Fig. 5O), and HEK-293T (Fig. 5P) cells treated with
mEAK-7 siRNAresulted in amarkeddefect ofwound closure after 2 days,
demonstrating that mEAK-7 is essential for cell migration in these cells.
The S6 kinases have differential functions mediated
through mEAK-7
Data from several sources suggest that S6 kinases play redundant roles
because of their high homology, but recent evidence reveals that the
independent role of S6K2 remains undetermined (28). Genome-wide
assessment of S6K1 and S6K2 in human tumors and in vitro silencing
of these kinases demonstrate that their targets are different from each
other and that S6K2more closelymirrors eIF4E function (33). S6K2 has
also been shown to be an essential regulator of cell proliferation, due to
its involvement with heterogeneous ribonucleoprotein F (34). Previous
reports demonstrate that S6 is essential for mammalian cell prolifera-
tion and that S6K1 controls eukaryotic size (35). Given that mEAK-7
regulates S6K2 function, we hypothesized that mEAK-7 also regulates
S6K2-mediated cell proliferation.
To determine the extent to which S6K2 regulates cell proliferation
and to compare its functional role in other mTOR targets, we treated
H1975 cells with control, S6K1, S6K2, or eIF4E siRNA for 48 hours in
DMEM+serum (Fig. 6A). Cells were then seeded into new tissue culture
plates andwere counted after 3 and 5 days. Treatment with S6K1, S6K2,
and eIF4E siRNA resulted in a significant reduction of cell proliferation
at days 3 and 5 (Fig. 6B). Treatment with S6K2 or eIF4E siRNAs signif-Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018icantly reduced cell proliferation at day 5, compared to S6K1 siRNA.
However, H1975 cells treated with S6K2 siRNA, compared to eIF4E
siRNA, did not result in a statistically significant reduction, suggesting
that S6K2 functions similarly to eIF4E with regard to cell proliferation,
as the literature reports (33). These results demonstrate that S6K2 is
essential for cell proliferation under these conditions.
mTOR signaling also controls cell size in eukaryotes (36). Because
we found that mEAK-7 is a positive activator of mTOR signaling, we
sought to determine the role of mEAK-7 in regulating cell size. H1975,
MDA-MB-231, and H1299 cells were treated with control or mEAK-7
siRNA for 48 hours, seeded onto new tissue culture plates, and pro-
cessed at day 3. Cells were analyzed on a Beckman Coulter CyAn 5 flow
cytometer for forward scatter. H1975 (fig. S9D),MDA-MB-231 (fig. S9E),
and H1299 (fig. S9F) cells treated with mEAK-7 siRNA resulted in an
increase in cell size, suggesting that dysfunctional S6K1 activity results
in aberrant cell size regulation after mEAK-7 knockdown. Under the
same conditions, cell size was also assessed using the Logos Biosystems
LunaCell Counter.H1975 (Fig. 6C),MDA-MB-231 (Fig. 6D), andH1299
(Fig. 6E) cells treated with mEAK-7 siRNA resulted in a significant in-
crease in cell size. These data demonstrate that whereas the loss of mEAK-7
resulted in decreased downstream mTOR signaling, aberrant activation of
S6K1 leads to dysregulation of cell size. In addition, H1975 cells were treated
with control, S6K1, or S6K2 siRNA and then analyzed via forward scatter in
flowcytometry.S6K1knockdownreducedcell size,whereasS6K2knockdown
demonstrated limited change in cell size (Fig. 6F).
Because overexpression of pcDNA3-HA-S6K2-WT or pRK7-HA-
S6K1-WT was not sufficient to rescue mTOR signaling in H1299 cells
treated with mEAK-7 siRNA (Fig. 4, I to M), we posited that this ob-
stacle could be overcome by transfecting cells with constitutively ac-
tivated forms of S6K1 or S6K2. To determine whether this could
rescue mEAK-7 knockdown effects, we treated cells with control siRNA,
mEAK-7 siRNA, mEAK-7 siRNA + pRK7-HA-S6K1-F5A-E389-
deltaCT (50 kDa—deletion that results in a truncated kinase) (cS6K1)
plasmid, or mEAK-7 siRNA + pcDNA3-HA-S6K2-E388-D3E (60 kDa)
(cS6K2) plasmid. Concomitant knockdownofmEAK-7 andoverexpres-
sion of cS6K1 and cS6K2 in H1299, H1975, andMDA-MB-231 cells re-
sulted in rescue of (Ser240/244) p-S6 levels (Fig. 6G). Knockdown of
mEAK-7 and overexpression of cS6K1 or cS6K2 resulted in partial res-
cue of cell proliferation defects (Fig. 6H). Thus, we demonstrate that
mEAK-7 functions upstream of S6K2 and promotes S6K2-mediated
signaling and proliferation.DISCUSSION
Here, we determined that mEAK-7 is an important, evolutionarily
conserved, lysosomal protein that activatesmTOR signaling in response
to nutrient stimulation in many cell types (Fig. 6I). We provide mech-
anistic insight for a novel protein that is required for serum-, amino
acid–, and insulin-mediated mTOR signaling in human cells. We also
demonstrate that mEAK-7 is necessary for S6K2 function by regulating
S6K2-mTOR interaction and 4E-BP1–eIF4E interaction and by sup-
porting cell proliferation and cellmigration inmEAK-7+ cells.We iden-
tifiedmEAK-7 as an essential interacting protein ofmTOR andmLST8,
but not of other mTORC1 components (raptor, DEPTOR, or PRAS40)
and mTORC2 components (rictor, DEPTOR, or Sin1). mEAK-7 inter-
acts withmTOR through theMTB domain (Fig. 6J). mEAK-7 regulates
the mTORC1 signaling at the lysosome and is a key player for mTOR
recruitment to the lysosome. Thus, we determined that mEAK-7 func-
tions as an essential component of mTOR signaling to regulate S6K210 of 15
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SC I ENCE ADVANCES | R E S EARCH ART I C L Eand 4E-BP1, through a potentially alternative pathway to the canonical
mTORC1 or mTORC2 models.
Since the discovery of rapamycin, decades of research have con-
tributed to understanding themechanism by whichmTOR is regulated
in response to nutrients and stress (3). The two best-known complexes
that contain mTOR are mTORC1 and mTORC2. mTORC1 is com-
posed of raptor, mLST8 or GbL, PRAS40, and DEPTOR (3). mTORC2
is composed ofmLST8, rictor,mammalian stress-activated protein kinase
interacting protein 1, Protor, DEPTOR, and Tti1 and Tel2 (3).
With the finding that mEAK-7 is an interacting and functioning
partner ofmTORandmLST8,weposited thatmEAK-7may formanovel
complex to regulate the specificity of S6K2 interaction with mTOR.
4E-BP1 binding to eIF4E is also affected by the loss of mEAK-7, and
our data suggest that a potential new complex may, in certain con-
texts, regulate this mTOR-mediated function as well. Our evidence
suggests that mEAK-7 functions at the level of mTOR as a coordinator
for S6K2 and 4E-BP1, but the downstream partners that mediate this
process remain unknown.
It has been theorized that additional mTOR complexes may com-
plement mTORC1 and mTORC2 in mammalians. Astrocytes of the
central nervous system provide one such example of how mTOR may
function in a cell type–dependentmanner. In this context, GIT1 functions
as an interacting partner ofmTOR that does not associate with either rap-
tor or rictor (37). This finding is intriguing because it demonstrates that
cell type specificitymay dictate themolecular landscape that allows for full
mTOR regulation and activation. mEAK-7 may have eluded previous
mTOR immunoprecipitation and mass spectrometry analyses because
it is found to a limited extent in human cells (Fig. 1C and figs. S1C
and S4C). It is also unknown where mEAK-7 is expressed during de-
velopment. The interaction between mEAK-7 and mTOR, as well as
the associated influence on S6K2 and 4E-BP1 functions, suggest that
there aremoremTORcomponents yet to be identified thatmay interact
in a cell type– or context-dependent manner (Fig. 6I).
Because we did not screen mEAK-7 in all human cell types, further
investigation of mEAK-7 in other physiological contexts is essential for
understanding how mEAK-7 functions in human development or dis-
ease. We provide molecular insight demonstrating that mEAK-7
supports the interaction of S6K2 and mTOR, but the full complement
of interacting partners is yet to be determined. In addition, evolutionary
differences arose between mEAK-7 and nematode EAK-7. Nematode
EAK-7 functions in parallel to Akt signaling to regulate DAF-16 (human
FoxO) during development and life span (1). We demonstrate that
mEAK-7 is essential for mTOR signaling to regulate S6K2 and 4E-
BP1, but nematodes only have one S6 kinase, RSKS-1. Thus, it is unclear
how, or whether, EAK-7 regulates TOR signaling in nematodes.
One of the challenges in studying mTOR in mammalian systems is
the difficulty of discerning tissue or organ-specific functions, because
knockout of major components of mTORC1 or mTORC2 results in
embryonic lethality (38). S6K1 is the best-studied target of mTOR in
eukaryotes. In mice, loss of S6K1 reduces weight and improves insulin
sensitivity with high-fat diets (HFDs) (39), whereas mice with a stan-
dard diet (SD) are glucose-intolerant, hypoinsulinemic, and have re-
duced b cell size (40). Intriguingly, loss of both S6K1 and S6K2
reverses the deleterious effects of S6K1 knockout mice, restores glucose
tolerance under an SD, and further improves glucose tolerance with
an HFD (41).
Because S6K2 has been studied to a lesser extent in the scientific
community, much less is known about the importance of S6K2 in
development, metabolism, and disease. Compared to WT mice, S6K1Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018null mice are much smaller, S6K2 null mice are slightly larger, and
double-knockout animals result in perinatal lethality (27). Recent data
suggest that S6K2 may not be a purely redundant kinase to S6K1 be-
cause S6K1 null mice demonstrate higher S6K2 expression in the liver,
muscles, thymus, and brain and because S6K2 remains responsive to
rapamycin-mediated inhibition of S6 phosphorylation in S6K1 null
mice (42). Thus, S6K2was largely neglected, and tissue-specific func-
tions of S6K2 are now beginning to be understood. The loss of S6K2
resulted in higher basal levels of insulin in plasma, 2.5×more b cellmass
with an SD, and improved glucose tolerance, as well as enhanced insulin
sensitivity with an HFD (43). In addition, single S6K2 knockout en-
hances ketone body production and increases peroxisome proliferator–
activated receptor a activity in the liver, and S6K1 knockout mice are
capable of maintaining (Ser240/244) p-S6 levels, whereas S6K2 knockout
mice are not, aswe have demonstrated (30). Thus, elucidating the role of
mEAK-7–mediated regulation of S6K2 and mTOR signaling in mam-
mals will further our understanding of diseases where hyperactivation
of mTOR signaling occurs through aberrant S6K2 activity.MATERIALS AND METHODS
Cell lines
H1299, H1975,MDA-MB-231, andHEK-293T cell lines were obtained
fromAmericanTypeCultureCollection.Other cell lysateswere donations
and used as part of the initial cell screen. For Fig. 1C and fig. S1C lysates,
the donor laboratories verified the cell lysates and hold the validation
paperwork. Cell lysates derived fromour laboratory are as follows: human
embryonic stem cell line H1 (undifferentiated), H1 endoderm (differ-
entiated to pancreatic progenitors), H1mesoderm (cardiac progenitors),
H1 ectoderm (neuronal progenitors), H1 embryoid body, and human
gingival fibroblasts (two different patients). The following cell lines were
donated:T.Carey:UM-SCC-1,UM-SCC-10A,UM-SCC-11A,UM-SCC-
14A, UM-SCC-17A, UM-SCC-17B, UM-SCC-74A, UM-SCC-74B, and
UM-SCC-81B; M. Cohen: H1975 and H1299; S. Takayama: MDA-MB-
231; and M. S. Wicha: BT474, HCC1937, MDA-MB-436, SK-BR-3,
SUM149, SUM159, T4D7, and MDA-MB-468.
Cell culture
For cell culture, cell lines were grown in DMEM [Thermo Fisher Scien-
tific (TFS), catalog #11995-073], without antibiotics/antimycotics and
supplemented with a concentration of 10% fetal bovine serum (FBS;
TFS, catalog #10437-036, lot #1399413) at 37°C in a 5.0% CO2 incuba-
tor. Cells were grown in Falcon Tissue Culture Treated Flasks T-75
[Fisher Scientific (FS), catalog #13-680-65] until 75% confluent and split
with 0.25% trypsin-EDTA (TFS, catalog #25200-056) for 5 min in the
37°C cell incubator. Cells were washed 1× with phosphate-buffered sa-
line (PBS) and resuspended in 10% FBS containing DMEM. Cells were
countedwith the LUNAAutomatedCell Counter [LB, catalog #L10001]
using LUNACell Counting Slides (LB, catalog #L12003) andAO-PI dye
(LB, catalog #F23001).
Starvation protocol
Cells were starved in DMEM−AAs (TFS, catalog #ME120086L1) for
50 min or 2 hours and then stimulated with amino acids (normal
DMEM), insulin (1 or 10 mM; Sigma-Aldrich, catalog #I9278-5ML),
or both for 30 or 60 min.
siRNA or plasmid transfection
Cells were seeded at a density of 500,000 cells per 60-mm tissue culture
plates (TCP) and grown for 24 hours. For siRNA transfection, we12 of 15
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#13778-150) within Opti-MEM I Reduced SerumMedium (TFS, catalog
#31985-070), and 100 nM siRNA was incorporated before being intro-
duced into cells at 100 nM concentration. For plasmid transfection, we
usedFuGENE6TransfectionReagent (Promega, catalog #E2691) intoOpti-
MEM I Reduced Serum Medium, and 2 mg of plasmid was incorporated
before being introduced into cells. For dual transfection, we added both
solutions. mEAK-7 siRNAs are identified as KIAA1609 or TLDC1: for
siRNA mEAK-7 #1 (TFS, ID #s33640), #2 (TFS, ID #HSS126697), #3
(TFS, ID #HSS126699). We also used the following siRNAs: mEAK-7
(TFS, ID #s33641, ID #s33642, and ID #HSS126698), S6K1 (TFS, ID
#s12282), S6K2 (TFS, ID #s12287), eIF4E (TFS, ID #s4578), and con-
trol (TFS, catalog #4390843). Plasmids were purchased from Addgene.
pRK7-HA-S6K1-WT was a gift from J. Blenis (Addgene, #8984).
pcDNA3-S6K2-WT was a gift from J. Blenis (Addgene, #17729). pRK7-
HA-S6K1-F5A-E389-deltaCT was a gift from J. Blenis (Addgene, #8990).
pcDNA3-S6K2-E388-D3E was a gift from J. Blenis (Addgene, #17731).
Immunoblot analysis
Cells were collected with a cell scraper and lysed in cold NP-40 lysis
buffer (50 mM tris, 150 mMNaCl, and 1.0% NP-40 at pH 8.0). Protein
lysate (50 mg) was separated in Novex WedgeWell 4-20% tris-glycine
gels (TFS; catalog #XP04205BOX) or 10% tris-glycine gels (TFS, cat-
alog #XP00105BOX). Proteins were transferred to polyvinylidene di-
fluoridemembranes, incubated with primary antibodies overnight at
4°C, and then incubated with secondary antibodies at room tempera-
ture for 1 hour.Membraneswere incubatedwith SuperSignalWest Pico
Chemiluminescent Substrate (TFS, catalog #34078) or Femto (TFS,
catalog #34095). Primary antibodies were as follows: mouse mono-
clonal antibody against mEAK-7 (KIAA1609) was obtained from
Origene Technologies (clone OTI12B1, formerly 12B1, catalog
#TA501037). All antibodies from CST were as follows: glycer-
aldehyde-3-phosphate dehydrogenase (catalog #2118S), (Ser240/244)
p-S6 ribosomal protein (2215S), S6 ribosomal protein (2217S),
(Thr389) p-p70 S6 kinase (9234S), S6K1 (2708S), S6K2 (14130S),
mTOR (2983S), HA-tag mouse (2367S), HA-tag rabbit (3724S),
(Ser65) p–4E-BP1 (9451S), (Thr37/46) p–4E-BP1 (9459S), (Thr70) p–
4E-BP1 (13396S), mLST8 (3274S), raptor (2280S), PRAS40 (2691S),
DEPTOR/DEPDC6 (11816S), rictor (2114S), Sin1 (12860S), 4E-BP1
(9452S), and eIF4E (2067S). Antibodies p-S6, S6, and 4E-BP1were used
at 1:3000 dilution and the remainder at 1:1000 dilution in 5% bovine
serum albumin (BSA) in 1× tris-buffered saline with Tween-20 (TBST)
buffer with 0.04% sodium azide. Secondary antibodies for immunoblot
analysis: 1:4000 dilution for an a-mouse IgG horseradish peroxidase
(HRP) conjugate (Promega, catalog #W4021) and 1:7500 dilution for
an a-rabbit IgG HRP conjugate (Promega, catalog #W4011).
Molecular cloning of HA–mEAK-7WT into mutants
GibsonAssembly reaction (NewEnglandBiolabs, catalog #E2611S)was
used to generatemutant constructs in accordance to themanufacturer’s
instructions. In table S1, we outline the list of primers used to produce
the different mutant plasmids and extended materials and methods.
pLenti-GIII-CMV–mEAK-7–HA (ABM Inc., catalog #LV198982)
was used as backbone. All mutants were confirmed by DNA sequencing.
For WT and mutant constructs, 10× lentiviral supernatant was prepared
by the Vector Core at the University of Michigan. H1299 cells were
infected with 1× virus and selected with puromycin (1 mg/ml) in
10%DMEM+serum. After 2 weeks, cells were used for immunoblot anal-
ysis and confocal microscopy.Nguyen et al., Sci. Adv. 2018;4 : eaao5838 9 May 2018Immunoprecipitation analysis
After siRNA and/or plasmid transfection, cells were harvested in 1%
NP-40 lysis buffer or CHAPS lysis buffer [FIVEphoton Biochemicals
(FB), catalog #CIB-1] supplemented with protease inhibitors (FB, catalog
#PI-1) and phosphatase inhibitors (FB, catalog #PIC1). Proteins (250 mg)
were used for immunoprecipitation reactions, and 25 mg of proteins was
used for whole-cell lysate analysis. Antibodies (2 mg) and 40 ml of Immu-
noCruz IP/WB Optima C agarose beads [Santa Cruz Biotechnology
(SCB), catalog #sc-45040] were incubated in 1 ml of PBS for 1 hour at
4°C. Separately, 250 mg of proteins was incubated with 50 ml of Pre-
clearingMatrix C (SCB, catalog #sc-45054) inCHAPS buffer for 1 hour.
After washing, the antibody-bead conjugate was incubated with pre-
cleared protein lysate for 1.5 hours at 4°C, and precipitated beads were
washed three times with PBS. Antibodies for immunoprecipitation were as
follows: goat anti-HAepitope tag (NovusBiologicals, catalog #NB600-362),
goat IgG (SCB, catalog #sc-2028),mTOR (CST, catalog #2983S),mEAK-7
(SCB, catalog #sc-247321), and eIF4E (SCB, catalog #sc-271480).
Cell immunofluorescence analysis
A total of 250,000 cells were seeded into a two-well Nunc Lab-Tek II
Chamber Slide System (FS, catalog #12-565-5) for 24 hours. Cells
were starved for 50 min in DMEM−AAs and stimulated with amino
acids or 1 mM insulin for 30 min. Then, cells were fixed with Z-Fix
solution (Anatech LTD, catalog #170) for 10 min at room temperature,
washed three times in PBS, and incubated with the following: un-
masking solution (PBS, 2N HCl, and 0.5% Triton X-100) for 10 min,
quenching solution (TBS and0.1% sodiumborohydride) for 10min, per-
meabilization solution (PBS and 0.02% Triton X-100) for 10 min,
and 5% BSA for 1 hour. Cells were incubated overnight at 4°C with
primary antibody. Next, slides were washed with PBS and incubated
in secondary antibodies for 1 hour at room temperature. We used a
Nikon Ti Eclipse confocal microscope (×100 magnification) to cap-
ture images. We captured images with or without 3× digital zoom,
1/32 frames/s, 1024 × 1024 image capture, 1.2 airy units, 2× line aver-
aging, appropriate voltage, and power settings optimized per antibody.
No modification was done, except image sizing reduction for figure
preparation. Quantitative analyses were completed via Imaris software
for confocal images with calculation of colocalization as percentages.
Identical threshold settings captured images across three to five individual
fields (10 to 15 cells) per condition, with the data representing at least
three independent experiments. Primary antibodies for immuno-
fluorescencewere as follows:mouseHA-tag (CST, catalog #2367S), rabbit
HA-tag (CST, catalog #3724S), LAMP1 (CST, catalog #9091S), LAMP2
(SCB, catalog #sc-18822), mEAK-7 (SCB, catalog #sc-247321), EEA1 en-
dosome (CST, catalog #3288S), AIFmitochondria (CST, catalog #5318S),
PDI endoplasmic reticulum (CST, catalog #3501S), RCAS-1 Golgi com-
plex (CST, catalog #12290S), and mTOR (1:1000) (CST, catalog #2983S).
All antibodies were used at 1:1500 with a working volume of 1.5ml in 5%
BSA in PBS, unless noted otherwise. Secondary antibodies for immuno-
fluorescence were as follows: donkey anti-mouse IgG Alexa Fluor 488
(TFS, catalog #R37114), donkey anti-rabbit IgGAlexaFluor 594 (TFS, cat-
alog #A-21207), and donkey anti-goat IgG Alexa Fluor 647 (TFS, catalog
#A-21447). All antibodies were used at a concentration of 1:1500 with a
workingvolumeof1.5ml in5%BSA inPBS.DAPI stainwasused forDNA.
Cell proliferation, size, migration, apoptosis, and scratch
wound assay analysis
For cell proliferation and size assay, cells were processedwith the LUNA
Automated Cell Counter (LB, catalog #L10001) using LUNA Cell13 of 15
SC I ENCE ADVANCES | R E S EARCH ART I C L ECounting Slides (LB, catalog #L12003) and AO-PI dye (LB, catalog
#F23001). After siRNA/plasmid transfection or lentiviral transduction,
200,000 cells were seeded in 100-mm TCPs for 3- and 5-day analysis.
All cell size data were processed at day 3. Cell size was consistent across
multiple platforms for analysis. For cell migration assay, cells were seeded
at a density of 50,000 cells per well in CIM-plate 16 (ACEA Biosciences,
catalog #05665817001). Real-time capture of cell migration was per-
formed over 48 hours on the xCELLigence System, RTCA DP Instru-
ment (ACEA Biosciences, catalog #00380601050) and processed by
RTCA Software 2.0. This technology is a widely used and validated tool,
with more than 1200 publications (https://aceabio.com/publications/).
Cells must pass through a pore embedded in a gold-plated electric grid,
creating electrical impedance and registering a signal for real-time,
quantifiable cell migration. As cells migrate through a small pore, they
pass over a gold grid, which causes electrical impedance that is registered
in real time as cellular migration. To prepare the data, we plotted the cell
index every 12 hours.We can distribute all data points upon request. For
scratch wound assays, cells were seeded at a density of 1,500,000 cells in
35-mm TCPs. After 24 hours, cell plates were linearly scratched with a
pipette tip, and images representative of wound healing were captured
after 48 hours. For cell size and death analysis via flow cytometry, cells
were analyzed for forward scatter with the BeckmanCoulter CyAn flow
cytometer at the University of Michigan Flow Cytometry Core. Cells
were analyzed by annexin V/PI staining with annexin V (TFS, catalog
#A13199) and PI (Sigma-Aldrich, catalog #25535-16-4), according to
the manufacturer’s protocols.
Statistical analysis
Cell proliferation,migration, and sizewere analyzed via paired Student’s
t test. Immunoblot and immunoprecipitation assays were repeated at
least three times in all cell lines.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/4/5/eaao5838/DC1
fig. S1. T-coffee analysis of mEAK-7 in eukaryotes, validation of human mEAK-7 antibody, and
an expanded cell screen for mEAK-7 protein.
fig. S2. Extended immunofluorescence analysis of HA–mEAK-7WT in other cellular
compartments.
fig. S3. Validation of mEAK-7 antibody for immunofluorescence analysis of endogenous mEAK-7.
fig. S4. mEAK-7 regulates serum-mediated activation of mTORC1 signaling and knockdown of
mEAK-7 results in increased (Thr389) p-S6K1 levels.
fig. S5. Densitometry analysis of Fig. 1I.
fig. S6. Densitometry analysis of Fig. 1J.
fig. S7. Immunofluorescence analysis of endogenous mEAK-7 colocalizing with endogenous
mTOR in response to nutrients and immunoprecipitation analysis of HA–mEAK-7 mutants for
mTOR interaction.
fig. S8. Densitometry analysis of Fig. 4.
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